Skip to main content
. 2022 Aug 29;76(3):e1157–e1165. doi: 10.1093/cid/ciac692

Figure 2.

Figure 2.

Desirability of outcome ranking distribution by treatment groups for each clinical trial analyzed. The events are defined in Figure 1 and include absence of clinical response, infectious complications, serious adverse events, and death. Abbreviations: DOR, doripenem; FDC, cefiderocol; FOS, fosfomycin; IMP, imipenem-cilastatin; LVX, levofloxacin; TZP, piperacillin/tazobactam.